2-甲氧基-N-[3-[(3-甲基苯甲酰)氨基]苯基]苯甲酰胺 | 947914-18-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-甲氧基-N-[3-[(3-甲基苯甲酰)氨基]苯基]苯甲酰胺
• 中文别名: 2-甲氧基-N-[3-[(3-甲基苯甲酰基)氨基]苯基]苯甲酰胺；2-甲氧基-N-(3-(3-甲基苯甲酰胺基)苯基)苯甲酰胺
• 英文名称: ML-365
• 英文别名: 2-methoxy-N-(3-(3-methylbenzamido)phenyl)benzamide；2-methoxy-N-[3-[(3-methylbenzoyl)amino]phenyl]benzamide
• CAS: 947914-18-3
• 化学式: C₂₂H₂₀N₂O₃
• 分子量: 360.412
• InChiKey: UTAJHKSGYJSZBR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  67.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  3-methyl-N-(3-nitrophenyl)benzamide 在 sodium tetrahydroborate 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 、 乙腈 为溶剂， 反应 8.0h， 生成 2-甲氧基-N-[3-[(3-甲基苯甲酰)氨基]苯基]苯甲酰胺
  参考文献：
  名称：

  Potent and selective inhibitors of the TASK-1 potassium channel through chemical optimization of a bis-amide scaffold

  摘要：

  TASK-1 is a two-pore domain potassium channel that is important to modulating cell excitability, most notably in the context of neuronal pathways. In order to leverage TASK-1 for therapeutic benefit, its physiological role needs better characterization; however, designing selective inhibitors that avoid the closely related TASK-3 channel has been challenging. In this study, a series of bis-amide derived compounds were found to demonstrate improved TASK-1 selectivity over TASK-3 compared to reported inhibitors. Optimization of a marginally selective hit led to analog 35 which displays a TASK-1 IC50=16 nM with 62-fold selectivity over TASK-3 in an orthogonal electrophysiology assay.

  DOI：

  10.1016/j.bmcl.2014.06.032

文献信息

• [EN] COMBINATION THERAPIES WITH FARNESOID X RECEPTOR (FXR) MODULATORS<br/>[FR] POLYTHÉRAPIES FAISANT APPEL À DES MODULATEURS DU RÉCEPTEUR DE FARNÉSOÏDE X (FXR)
  申请人：AKARNA THERAPEUTICS LTD

  公开号：WO2017205684A1

  公开（公告）日：2017-11-30

  Described herein are methods of treating a metabolic disorder in an individual in need thereof, comprising co-administering to the individual a therapeutically effective amount of an FXR modulator, and at least one second agent that is an CCR2/CCR5 antagonist, ASKl inhibitor, DPP-IV inhibitor, caspase protease inhibitor, SGLT2 inhibitor, acetyl-CoA carboxylase (ACC) inhibitor, diacyl glycerol acyltransferase-1 inhibitor, sodium -bile acid cotransporter-inhibitor, TLR-4 antagonist, PPAR alpha/delta agonist, or GLP-1 agonist, or a combination thereof.

  本文描述了治疗需要的个体中的代谢紊乱的方法，包括向该个体共同给予治疗有效量的FXR调节剂和至少一种第二药物，该第二药物是CCR2/CCR5拮抗剂、ASKl抑制剂、DPP-IV抑制剂、半胱氨酸蛋白酶抑制剂、SGLT2抑制剂、乙酰辅酶A羧化酶（ACC）抑制剂、二酰甘油酰转移酶-1抑制剂、钠-胆汁酸共转运抑制剂、TLR-4拮抗剂、PPAR alpha/delta激动剂或GLP-1激动剂，或其组合。
• Synthesis and SAR of novel, non-MPEP chemotype mGluR5 NAMs identified by functional HTS
  作者：Ya Zhou、Alice L. Rodriguez、Richard Williams、C. David Weaver、P. Jeffrey Conn、Craig W. Lindsley

  DOI：10.1016/j.bmcl.2009.10.059

  日期：2009.12

  This Letter describes the discovery and SAR of three novel series of mGluR5 non-competitive antagonists/negative allosteric modulators (NAMs) not based on manipulation of an MPEP/MTEP chemotype identified by a functional HTS approach. This work demonstrates fundamentally new mGluR5 NAM chemotypes with submicromolar potencies, and further examples of a mode of pharmacology 'switch' to provide PAMs with a non-MPEP scaffold. (C) 2009 Elsevier Ltd. All rights reserved.
• COMBINATION THERAPIES WITH FARNESOID X RECEPTOR (FXR) MODULATORS
  申请人：Akarna Therapeutics, Ltd.

  公开号：EP3463373A1

  公开（公告）日：2019-04-10
• KCNK3-BASED GENE THERAPY OF CARDIAC ARRHYTHMIA
  申请人：Universität Heidelberg

  公开号：EP3694996A1

  公开（公告）日：2020-08-19
• [EN] KCNK3-BASED GENE THERAPY OF CARDIAC ARRHYTHMIA<br/>[FR] THÉRAPIE GÉNIQUE DE L'ARYTHMIE CARDIAQUE À BASE DE KCNK3
  申请人：UNIV HEIDELBERG

  公开号：WO2019073058A1

  公开（公告）日：2019-04-18

  The present invention relates to an antagonist of the Two-Pore Domain Potassium Channel (TASK- 1) K2P3.1 for use in the prevention and/or treatment of cardiac arrhythmia in a subject. The invention also relates to a nucleic acid molecule usable in the prevention and/or treatment of cardiac arrhythmia in a subject. The invention further relates to a cell comprising said nucleic acid molecule. The invention further relates to a vector comprising said nucleic acid molecule.